Abstract

BackgroundRecent evidence suggests that there is often substantial variation in the benefits and harms across a trial population. We aimed to identify regression modeling approaches that assess heterogeneity of treatment effect within a randomized clinical trial.MethodsWe performed a literature review using a broad search strategy, complemented by suggestions of a technical expert panel.ResultsThe approaches are classified into 3 categories: 1) Risk-based methods (11 papers) use only prognostic factors to define patient subgroups, relying on the mathematical dependency of the absolute risk difference on baseline risk; 2) Treatment effect modeling methods (9 papers) use both prognostic factors and treatment effect modifiers to explore characteristics that interact with the effects of therapy on a relative scale. These methods couple data-driven subgroup identification with approaches to prevent overfitting, such as penalization or use of separate data sets for subgroup identification and effect estimation. 3) Optimal treatment regime methods (12 papers) focus primarily on treatment effect modifiers to classify the trial population into those who benefit from treatment and those who do not. Finally, we also identified papers which describe model evaluation methods (4 papers).ConclusionsThree classes of approaches were identified to assess heterogeneity of treatment effect. Methodological research, including both simulations and empirical evaluations, is required to compare the available methods in different settings and to derive well-informed guidance for their application in RCT analysis.

Highlights

  • Evidence based medicine (EBM) has heavily influenced the standards of current medical practice

  • Randomized clinical trials (RCTs) and meta-analyses of Randomized Controlled Trial (RCT) are regarded as the gold standards for determining the comparative efficacy or effectiveness of two treatments within the EBM framework

  • Analysis of heterogeneity of treatment effect (HTE), i.e. non-random variation in Rekkas et al BMC Medical Research Methodology (2020) 20:264 the direction or magnitude of a treatment effect for subgroups within a population [8], is the cornerstone of precision medicine; its goal is to predict the optimal treatments at the individual level, accounting for an individual’s risk for harm and benefit outcomes

Read more

Summary

Introduction

Evidence based medicine (EBM) has heavily influenced the standards of current medical practice. Randomized clinical trials (RCTs) and meta-analyses of RCTs are regarded as the gold standards for determining the comparative efficacy or effectiveness of two (or more) treatments within the EBM framework. Within this framework, as described in Guyatt et al’s classic User’s Guide to the Medical Literature II [1], “if the patient meets all the [trial] inclusion criteria, and doesn’t violate. Analysis of heterogeneity of treatment effect (HTE), i.e. non-random variation in Rekkas et al BMC Medical Research Methodology (2020) 20:264 the direction or magnitude of a treatment effect for subgroups within a population [8], is the cornerstone of precision medicine; its goal is to predict the optimal treatments at the individual level, accounting for an individual’s risk for harm and benefit outcomes. We aimed to identify regression modeling approaches that assess heterogeneity of treatment effect within a randomized clinical trial

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call